Spread the love

Remember the Project Veritas journalist from Fox News that went public about the censorship of her Covid drug treatment coverage?

The brave reporter’s name is Ivory Hecker, and since going public, she has been terminated from Fox News.

That hasn’t stopped Ivory Hecker from uncovering the truth.

She is back with her newly released first independent report, deep-diving into alternative Covid treatments.

In her report, Hecker interviews Dr. Joseph Varon, the chief medical officer from Houston, Texas.

Who is Dr. Varon?

He worked for 400 days straight to research the Covid virus, and during that time, he has uncovered some groundbreaking findings.

However, when he tried to share the news with the mainstream media, Dr. Varon found himself censored.

The mainstream media wasn’t ready for the good news that Dr. Varon’s treatment method had a great success rate.

What did Dr. Varon do that necessitated censorship?

He used the “Math+ protocol” on his Covid patients.

This protocol prioritizes steroids and blood thinners as well as vitamins through an IV, including Ivermectin.

Dr. Varon says Ivermectin was responsible for the high success rate and is efficacious against Covid.

Hecker posted her interview with Dr. Varon on Bitchute.

We also have it so you can watch safely on Rumble below:

Did the pharmaceutical industry see Dr. Varon’s studies as a threat and censor his findings?

If Ivermectin were widely used in the early stages of Covid, then there would be less dependency on a “vaccine.”

Dr. Varon says his life-saving treatment method needs to be told to the world.

Interestingly, other counties are pursuing Ivermectin to treat Covid.

In the UK, studies have begun looking at Ivermectin’s efficacy in the treatment of Covid.

Yahoo News has more:

Ivermectin, a widely used anti-parasitic drug, is to be investigated as a possible treatment for Covid-19, researchers have announced.

The drug, used across the world to treat parasitic infections, will be studied as part of Oxford University’s Principle trial – which is dedicated to finding at-home medicine for speeding up recovery from or preventing hospitalisation with Covid-19.

Ivermectin has been controversially touted as a potential treatment for Covid since the earliest stages of the pandemic.

Although the drug is not an antiviral, laboratory-based studies have found that it can block replication of Sars-CoV-2 – the virus that causes Covid-19 – but at much higher, and unsafe, concentrations than those used in currently authorised ivermectin treatments.

Results from clinical studies were varied, with some studies showing no effect and others reporting that ivermectin has a potential benefit, in terms of reducing viral load and the duration of symptoms in some patients with mild Covid.

However, the lack of evidence from large-scale, randomised controlled trials has made it impossible to say with confidence that the drug is effective in treating Covid – though some countries, such as Peru, Bolivia and Colombia, have decided to nonetheless push ahead with administering ivermectin to patients.

The US Food and Drug Administration has previously warned against using ivermectin to treat or prevent Covid-19, while a European Medicines Agency review in March concluded that “the available data do not support its use for Covid-19 outside well-designed clinical trials”.

Oxford’s professor Chris Butler, the joint chief investigator of the Principle trial, said his team hopes “to generate robust evidence to determine how effective the treatment is against Covid-19, and whether there are benefits or harms associated with its use.”

He said the drug is readily available on a global level and is well known to have a “good safety profile”.

Participants enrolled in the study will be randomly assigned a three-day course of ivermectin treatment. They will be followed-up for 28 days and will be compared with trialists who receive the usual standard of NHS care only.

Dr Stephen Griffin, a virologist at the University of Leeds, said the drug’s inclusion in the Principle trial “should provide a final answer to the questions over whether this drug might be repurposed as an antiviral targeting Sars-CoV-2”.

“Much like hydroxychloroquine before, there has been a considerable amount of off-label use of this drug, based primarily upon in vitro cell culture data,” he said.

“However, antiviral effects have only been demonstrated in such systems at concentrations much higher than those corresponding to routine anti-parasitic treatment.”

Ivermectin is the seventh treatment to be investigated by the Principle trial, and is being evaluated alongside the influenza antiviral favipiravir.

In April, researchers from the study found that budesonide, a medicine used for asthma, can shorten the recovery time of Covid-19 sufferers who do not need hospital treatment by an average of three days.

The readily available drug, administered via a cheap inhaler twice a day for up to 14 days, is being prescribed by GPs on a “case-by-case basis”, allowing doctors to treat Covid-19 patients at home.

Ivermectin’s admission to the Principle trial will be closely monitored by the government’s taskforce dedicated to searching and developing a new generation of drugs capable of treating people with coronavirus in their own homes.

The taskforce, modelled on the team responsible for the UK’s vaccine programme, is aiming to identify and support research into promising antiviral treatments that can reduce transmission and speed up recovery from Covid-19.

It’s hoped two effective treatments – offered in tablet form – will be made available to the public as early as autumn, providing Britain with “another layer of defence” alongside the vaccines in combating possible future waves and emerging variants, said Sir Patrick Vallance in April.

Indonesia is also testing Ivermectin in Covid treatments:

Eight hospitals in Indonesia are set to conduct clinical trials on Ivermectin, an anti-parasitic medicine that has appeared to be a potential COVID-19 medication, following a permit issued by the national agency of drug and food control (BPOM).

BPOM’s head Penny K. Lukito said at a press conference on Monday that global data and guidelines from the World Health Organization (WHO) show that Ivermectin, previously used for deworming, can also be used for COVID-19 treatment. However, data are still being collected and the results are not conclusive.

Clinical trials are expected to be conducted over a period of three months.

The list of countries moving forward with Ivermectin treatment continues to grow:

Ivermectin saves lives, yet the mainstream media remains silent about this life-saving treatment.

Instead, the mainstream media talks about critical race theory every day, glorifying the wrong heroes.

We all know that the true heroes in the pandemic are the doctors who pursued the truth amid Communist-level censorship.

Leave a Reply

Your email address will not be published. Required fields are marked *